New kidney drug candidate SK-09 enters first human safety tests

NCT ID NCT07267026

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new oral drug called SK-09 in 72 healthy adults to see if it is safe and how the body processes it. The study is split into two parts: one where participants get a single dose, and another where they get multiple doses. No one knows who gets the drug or a placebo. This research is a first step before testing the drug in people with kidney diseases like FSGS and MCD.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FSGS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal segmental glomerulosclerosis macular corneal dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Q-Pharm Pty Ltd.

    RECRUITING

    Herston, Queensland, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••